Brain-derived neurotrophic factor (BDNF) as a predictor of treatment response in major depressive disorder (MDD): a systematic review
MI Zelada, V Garrido, A Liberona, N Jones… - International Journal of …, 2023 - mdpi.com
Brain-derived neurotrophic factor (BDNF) has been studied as a biomarker of major
depressive disorder (MDD). Besides diagnostic biomarkers, clinically useful biomarkers can …
depressive disorder (MDD). Besides diagnostic biomarkers, clinically useful biomarkers can …
[HTML][HTML] Effects of perioperative use of esketamine on postpartum depression risk in patients undergoing cesarean section: a randomized controlled trial
QR Liu, QK Zong, LL Ding, HY Dai, Y Sun… - Journal of affective …, 2023 - Elsevier
Background Postpartum depression (PPD) is a prevalent public health issue. Although
ketamine has prophylactic effects on PPD in women undergoing cesarean section, the …
ketamine has prophylactic effects on PPD in women undergoing cesarean section, the …
Ketamine treatment for anhedonia in unipolar and bipolar depression: A systematic review
A Kwaśny, J Kwaśna, A Wilkowska, J Szarmach… - European …, 2024 - Elsevier
Ketamine, an N-methyl-D-aspartate receptor antagonist, is a racemic mixture of esketamine
and arketamine used to treat unipolar and bipolar depression. Preliminary reports indicate …
and arketamine used to treat unipolar and bipolar depression. Preliminary reports indicate …
TCF4 and RBFOX1 as peripheral biomarkers for the differential diagnosis and treatment of major depressive disorder
K Xu, Y Ren, L Fan, S Zhao, J Feng, Q Zhong… - Journal of Affective …, 2024 - Elsevier
Background Recent genome-wide association studies on major depressive disorder (MDD)
have indicated the involvement of LRFN5 and OLFM4; however, the expression levels and …
have indicated the involvement of LRFN5 and OLFM4; however, the expression levels and …